一种用于脓毒症辅助诊断的检测试剂盒及其制备方法
By combining nuclear membrane-protected cell nuclear extraction technology with CD63 flow cytometry antibody detection, the problem of false positives caused by nuclear membrane damage has been solved, enabling accurate detection of CD63 expression levels in neutrophil nuclear membranes and improving the specificity and sensitivity of early diagnosis of sepsis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- THE FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY
- Filing Date
- 2026-05-21
- Publication Date
- 2026-07-17
AI Technical Summary
In existing technologies, the detection of CD63 in the nuclear membrane of neutrophils suffers from a high false positive rate, mainly due to CD63 leakage caused by nuclear membrane damage and false positive signals generated by commercial CD63 antibodies penetrating the nuclear membrane, resulting in a lack of specificity and accuracy for early diagnosis.
Nuclear membrane protected extraction technology was employed, using a nuclear membrane protected cell nuclear extraction reagent composed of specific blood-free negative selection magnetic beads and cytoplasmic temperature lysis buffer A. Combined with the synergistic detection of CD63 flow cytometry antibody and Lamin B1 antibody, a nuclear membrane integrity detection control was introduced. Fluorescent groups were linked through PEG flexible spacer arms to reduce steric hindrance, and artificially induced positive controls were set up for quality control.
It effectively eliminates interference from nuclear membrane damage, improves the specificity and sensitivity of the detection, ensures the accuracy of CD63 expression levels in neutrophil nuclear membranes, and enhances the early auxiliary diagnostic capability of sepsis.
Smart Images
Figure CN122218209B_ABST